MRK Meets Endpoints
Merck's Tulisokibart meets primary and key secondary endpoints in Phase 3 ATLAS-UC induction-only study for ulcerative colitis
MRK Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)